Ionis Pharma's danvatirsen shows positive effect in mid-stage head and neck cancer study; shares up 4% [Seeking Alpha]
Ionis Pharmaceuticals, Inc. (IONS)
Last ionis pharmaceuticals, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ionispharma.com
Company Research
Source: Seeking Alpha
Results from a Phase 1b/2 clinical trial evaluating Ionis Pharmaceuticals' ( IONS ) antisense drug danvatirsen (AZD9150), combined with AstraZeneca's ( AZN ) PD-L1 inhibitor Imfinzi (durvalumab), in patients with recurrent metastatic head and neck cancer showed a treatment effect. The data were presented at ESMO in Munich. Patients receiving the combo showed a response rate of 23%, including a 7% complete response rate, double the rate for durvalumab alone. Advancement into Phase 2 triggered a $17.5M milestone payment to IONS from AZN. #ESMO See all stocks on the move » Now read: Novo Nordisk Could Benefit From Latest FDA Warning » Subscribe for full text news in your inbox
Show less
Read more
Impact Snapshot
Event Time:
IONS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IONS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IONS alerts
High impacting Ionis Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
IONS
News
- Ionis Publishes 2023 Corporate Responsibility Report [Yahoo! Finance]Yahoo! Finance
- Ionis Publishes 2023 Corporate Responsibility ReportPR Newswire
- n-Lorem Foundation Partners with Hongene Biotech Corporation to Support the Discovery of Personalized ASO Medicines for Nano-rare Patients [Yahoo! Finance]Yahoo! Finance
- Ionis to hold first quarter 2024 financial results webcastPR Newswire
- Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 [Yahoo! Finance]Yahoo! Finance
IONS
Earnings
- 2/21/24 - Beat
IONS
Sec Filings
- 4/25/24 - Form ARS
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form DEF
- IONS's page on the SEC website